Introduction {#S1}
============

*Escherichia coli* is both a commensal microorganism and a major pathogen in humans and animals. *E. coli* has also been recognized as a multi-sectoral indicator of the antimicrobial resistance (AMR) burden due to its large distribution in a wide range of ecosystems. Concerning AMR, most data on *E. coli* have focused on resistance to extended-spectrum cephalosporins (ESCs), conferred either by extended-spectrum beta-lactamases (ESBLs) or plasmid-mediated cephalosporinases (pAmpCs), and numerous cross-sectional studies have investigated ESC-resistant (ESC-R) *E. coli* to decipher possible transfers across sectors. In particular, several studies have demonstrated the transmission of ESC-R *E. coli* between humans and dogs, mostly within households ([@B33]; [@B21]). Overall, the distribution of ESC-R *E. coli* in dogs shows a wide diversity of lineages together with a few dominant clones, namely of sequence type (ST)648, ST410, and to a lesser extent, the human-associated ST131 ([@B16]; [@B17]; [@B38]).

More globally, humans and dogs share common diseases caused by extra-intestinal pathogenic *E. coli* (ExPEC) ([@B30]; [@B35]), of which urinary tract infections (UTIs) are by far the most common. Transmission of ExPEC between dogs and their owners has also been described ([@B13]; [@B43]; [@B12]), and contact with dogs or dog feces is considered a risk factor for the acquisition of resistant ExPEC ([@B50]). Nonetheless, due to frequent focus on AMR, the population structure of pathogenic *E. coli* that have not been studied for their resistance phenotype remains largely under-reported. A recent study showed the dominance of specific ExPEC lineages in dogs in the United States, such as the primarily dog-associated ST372 or the human-associated ST73, ST12, or ST127 ([@B30]). Uropathogenic *E. coli* (UPEC), which are a sub-pathotype of ExPEC mostly found in human infections, have often been associated with four major ST complexes: ST14, ST69, ST73, and ST95 ([@B29]; [@B31]; [@B18]). ST73 in particular may be an underestimated human UPEC because it is not often associated with ESC-R determinants ([@B35]). Furthermore, ESC-R *E. coli* show lower virulence scores, except for the *iutA* gene ([@B30]; [@B56]). Interestingly, a reduced virulence load in multidrug-resistant *E. coli*, concomitant to an increased prevalence of virulence genes in susceptible *E. coli* belonging to the phylogroup B2, has also been reported in isolates from Germany and Switzerland ([@B52]; [@B56]).

To characterize the *E. coli* lineages causing diseases in French dogs and to assess to what extent this population structure may include ExPEC and/or UPEC lineages causing diseases in humans, we investigated 618 non-duplicate clinical *E. coli* isolates collected from dogs throughout France in 2017. This was done independently of their resistance phenotype to correctly estimate the resistance and virulence load which can potentially be transmitted to (or from) humans.

Materials and Methods {#S2}
=====================

Bacterial Isolates {#S2.SS1}
------------------

*Escherichia coli* isolates (*n* = 618) were collected from four veterinary diagnostic laboratories in France between January and November 2017. The four laboratories were asked to provide all non-duplicate *E. coli* isolates causing diseases in dogs over a continuous 3-month period of time in 2017. Two laboratories were located in the Parisian suburbs, one in the Rhône département and one in the Alpes-Maritimes département. Three laboratories were referee laboratories (the two Parisian laboratories and the one from the Rhône département), receiving samples from all across France, such that the sampling of this study was considered representative of clinical *E. coli* isolates circulating in dogs in France. Most *E. coli* isolates were recovered from UTIs (*n* = 403, 65.2%) ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}), but also unexpectedly in a few cases of diarrhea (*n* = 29, 4.7%). Considering the ubiquitous presence of *E. coli*, we cannot completely exclude that a few isolates included in this study were not pathogenic. However, maximum precautions were taken to avoid this bias, since samples were all taken by veterinarians suspecting infectious diseases and since polycontaminated samples (≥3 bacteria growing on one plate) were not processed. Bacterial isolation was performed on Eosin Methylene Blue agar (EMB; ThermoFisher Diagnostics, Dardilly, France), Brillance^TM^ UTI agar (Oxoid), chromID^®^ CPS^®^ Elite agar (BioMérieux, Marcy l'Etoile, France) or blood agar, and identification was performed using MALDI-TOF mass spectrometry or API^®^ gallery-based identification according to each veterinary laboratory's methodology. All isolates were sent to the ANSES laboratory in Lyon for further characterization.

Antimicrobial Susceptibility Testing {#S2.SS2}
------------------------------------

Susceptibility testing was performed using the disk-diffusion test on Mueller--Hinton agar (BioRad, Marne-la-Coquette, France), according to the guidelines of the Antibiogram Committee of the French Society for Microbiology ([@B7]) and using clinical breakpoints referenced in the veterinary part of the CA-SFM (2019). For antibiotics that are not veterinary-licensed, such as carbapenems, breakpoints recorded in the human part of the CA-SFM were used. The following antibiotics of human and/or veterinary interest were tested: amoxicillin, amoxicillin + clavulanic acid, cefalotin, cefuroxime, cefotaxime, ceftiofur, piperacillin, ticarcillin, piperacillin + tazobactam, ticarcillin + clavulanic acid, ertapenem, ceftazidime, cefoxitin, cefepime, aztreonam, cefquinome, streptomycin, kanamycin, amikacin, apramycin, gentamicin, tobramycin, netilmicin, chloramphenicol, florfenicol, tetracycline, colistin, sulfonamides, trimethoprim, nalidixic acid, enrofloxacin, and ofloxacin. *E. coli* ATCC 25922 was used as a quality control.

Identification of β-Lactamase and Virulence Genes {#S2.SS3}
-------------------------------------------------

Each mix PCR (20 μL) contained 2 μL of DNA lysate, primers (0.5 μM); dNTP (0.2 mM), 1 U of *Taq* polymerase (Promega GoTaq^®^ G2) and 4 μL 5X *Taq* Buffer (Promega) qsp H~2~O. Multiplex PCRs were performed using the Multiplex PCR kit (Qiagen, France) according the manufacturer's instructions. PCR products were run and analyzed using a QIAxcel Advanced system (Qiagen, Courtaboeuf, France).

### Resistance Genes {#S2.SS3.SSS1}

PCRs were performed using specific primers for the detection of the ESBL genes *bla*~CTX--M~ group 1 and group 9, and *bla*~CTX--M--2~ ([@B45]; [@B14]). For all *bla*~CTX--M~ group 1 and group 9 isolates, additional PCRs were performed to identify the exact *bla*~CTX--M~ gene variant using the ISEcp1L1/P2D and MA1/MA2 primers, respectively. The *bla*~CMY~ genes were detected using CF1/CF2 primers ([@B15]). All positive amplicons were sequenced (Genewiz, London, United Kingdom).

### Virulence Genes {#S2.SS3.SSS2}

Two multiplex PCRs targeting seven genes (*focG*, *kpsMTII*, *papA*, *sfaS*, *afaD, hlyD*, *iutA*) related to ExPEC status were performed as previously described ([@B19]). In this study only the *papA* gene from the *pap* locus was considered for the ExPEC definition. The detection of two UPEC-associated genes (*cnf1/cnf2*, and *hlyD*) was done using previously described primers ([@B49]; [@B28]). PCRs targeting six additional ExPEC-associated virulence genes (*cdtB, iroN, ideA, iss*, *fimH*, and *fyuA)* were performed using specific primers ([@B40]; [@B28]; [@B46]; [@B53]). The *aggR* gene related to entero-aggregative *E. coli* (EAEC) was detected as described in a previous study ([@B20]). The *stx1*, *stx2*, and *eae* genes associated with the Entero-Haemorrhagic *E. coli* (EHEC) pathovar were identified using published primers ([@B8]; [@B39]; [@B11]).

Isolates carrying at least two of the following genes *papA*, *sfaS*-*focG*, *afaD, kpsMTII* and *iutA* were classified as ExPEC as described ([@B26]). *E. coli* isolates that possessed at least two ExPEC determinants and the additional haemolysin secretion protein D gene *hlyD* and the cytotoxic necrotizing factor *cnf1* were classified as UPEC, as previously defined ([@B25]).

Genetic and Molecular Typing of the Strains {#S2.SS4}
-------------------------------------------

Phylogenetic grouping of the *E. coli* isolates was performed using a published improved method ([@B9]). The B2-O25b-ST131 clone of *E. coli* was detected using a published PCR-based assay ([@B10]). Multi-locus sequence typing (MLST) of all ESBL/pAmpC/carbapenem-producing isolates (*n* = 34) was performed according to the Achtman protocol described on the *E. coli* MLST website^[1](#footnote1){ref-type="fn"}^. The complete MLST scheme was also performed on a randomly selected subset of 89 non-ESBL isolates belonging to the B2 phylogroup. For the remaining *E. coli* isolates belonging to the B2 phylogroup (*n* = 392), the *fumC* allele was sequenced as a reliable indicator of the MLST types ST372 (*fumC103*), ST73 (*fumC24*), ST141 (*fumC52*), and ST131 (*fumC40*). The *purA* and *icd* alleles were further sequenced for a subset of isolates presumably belonging to ST12 (*fumC13* and *purA10*), ST127 (*fumC14* and *icd36*), or ST961 (*fumC13* and *purA126*). ST131 clones were screened using PCR ([@B10]). For ST131-positive isolates, allelic variants of *fimH* were identified by PCR and sequencing. The presence of a C1-M27 cluster was determined using previously published PCRs targeting the cluster-specific prophage-like region (M27PP1) ([@B3]).

Plasmid Characterization {#S2.SS5}
------------------------

Plasmids were typed using PCR-based replicon typing (PBRT) according to the published PBRT kit scheme using a commercial kit (Diatheva, Cartoceto, Italy) ([@B6]). Plasmids carrying the ESBL/pAmpC/carbapenme-resistance genes were detected using PFGE-S1 gels (6 V/cm for 20 h with an angle of 120° at 14°C with pulse times ranging from 1 to 30 s) followed by Southern blot using adequate probes ([@B14]). After electrical transfer of DNA to nylon membranes, Southern blots were performed according to the manufacturer's protocol (Roche Diagnostics, Meylan, Germany). After overnight hybridization at 37°C, all membranes were treated with maleic acid and blocking solution for 45 min, then with purified anti-digoxigenin-AP Fab fragments, washing buffer and finally stained with NBT/BCIP. Plasmid co-localization was assessed by comparison between the bands corresponding to the resistance gene and those corresponding to the Inc type of the plasmid. The chromosomal location was identified by PFGE on *I-Ceu*1-digested DNA, followed by Southern blot hybridization using a 16S rDNA probe and probes specific to resistance genes.

Whole Genome Sequencing {#S2.SS6}
-----------------------

Whole genome sequencing (WGS) of 14 isolates was performed. Isolates were chosen because (i) they were classified as UPECs, (ii) they belonged to major STs, and (iii) they presented diverse virulence patterns. These 14 *E. coli* belonged to various STs (ST73, *n* = 4; ST372, *n* = 2; ST131, *n* = 3; ST141, *n* = 2; ST12 variant, *n* = 1; ST1262 variant, *n* = 1; ST2015, *n* = 1) was performed using the NextSeq technology (Illumina) from genomic DNA extracted from an overnight culture using the NucleoSpin^®^ Microbial DNA kit (Macherey Nagel, Germany). After trimming (using Trimmomatic), SPAdes (version 3.9) *de novo* assembly was performed using the Center for Genomic Epidemiology (CGE) server^[2](#footnote2){ref-type="fn"}^. Contigs shorter than 200 bp were filtered out. Contigs were annotated using the National Center for Biotechnology Information (NCBI) Prokaryotic Genomes Automatic Annotation Pipeline (PGAP) on <http://www.ncbi.nlm.nih.gov/genomes/static/Pipeline.html>. Virulence factors (VFs), resistance genes, STs and serotypes were identified from the assembled genomes according to VirFinder, ResFinder, and MLST finder from CGE (see text footnote 2).

Statistical Analysis {#S2.SS7}
--------------------

Fisher's exact test was used to determine whether proportions for one variable (antimicrobial susceptibility ([Table 1](#T1){ref-type="table"}) or multidrug-resistance ([Table 2](#T2){ref-type="table"}) or the distribution of virulence gene ([Table 3](#T3){ref-type="table"}) are different between phylogroups. The tests were considered significant when *p*-values were ≤0.05. When the Fisher's exact test was significant, an analysis and graphic visualization of the proportions and their 95% confidence intervals (CI) were performed. A proportion was considered significant when its CI did not overlap at least one other CI.

###### 

Antimicrobial resistance detected in the 618 studied *Escherichia coli* isolates.

  **Antibiotic**    **Number (%) of isolates**   **Total**   ***p-*value (Fisher's exact test)**                            
  ----------------- ---------------------------- ----------- ------------------------------------- ----------- ------------ -------------
  Amoxicillin       22 (62.9)                    30 (56.6)   **92 (18.7)^1^**                      26 (68.4)   170 (27.5)   \<2.2E-16
  AMC               12 (34.3)                    10 (18.9)   **12 (2.4)**                          11 (28.9)   45 (7.3)     \<2.2E-16
  Cefalotin         12 (34.3)                    9 (17.0)    **15 (3.0)**                          11 (28.9)   47 (7.6)     1.27*E*−13
  Cefuroxime        18 (51.4)                    16 (30.2)   **45 (9.1)**                          16 (42.1)   95 (15.4)    1.652*E*−14
  Cefotaxime        10 (28.6)                    5 (9.4)     **12 (2.4)**                          10 (26.3)   37 (6.0)     2.57*E*−11
  Ceftiofur         10 (28.6)                    4 (7.5)     **11 (2.2)**                          9 (23.7)    34 (5.5)     8.35*E*−11
  Ertapenem         0 (0)                        0 (0)       0 (0)                                 1 (2.6)     0 (0)        \>0.05
  Ceftazidime       9 (25.7)                     6 (11.3)    **11 (2.2)**                          10 (26.3)   36 (5.8)     2.98*E*−11
  Cefoxitin         1 (2.9)                      7 (13.2)    **10 (2.0)**                          9 (23.7)    27 (4.4)     1.08*E*−07
  Cefquinome        9 (25.7)                     8 (15.1)    **3 (0.6)**                           3 (7.9)     23 (3.7)     1.49*E*−12
  Streptomycin      15 (42.9)                    18 (34.0)   **55 (11.2)**                         15 (39.5)   103 (16.7)   1.72*E*−10
  Kanamycin         9 (25.7)                     5 (9.4)     **14 (2.8)**                          7 (18.4)    35 (5.7)     7.11*E*−08
  Amikacin          0 (0)                        0 (0)       0 (0)                                 0 (0)       0 (0)        \>0.05
  Apramycin         0 (0)                        0 (0)       0 (0)                                 0 (0)       0 (0)        \>0.05
  Gentamicin        9 (25.7)                     0 (0)       **3 (0.6)**                           5 (13.2)    17 (2.8)     4.29*E*−11
  Tobramycin        9 (25.7)                     0 (0)       **4 (0.8)**                           5 (13.2)    18 (2.9)     1.56*E*−10
  Netilmicin        7 (20.0)                     0 (0)       **1 (0.2)**                           1 (2.6)     9 (1.5)      3.0*E*−8
  Chloramphenicol   13 (37.1)                    3 (5.7)     **23 (4.7)**                          6 (15.8)    45 (7.3)     4.53*E*−08
  Tetracycline      20 (57.1)                    12 (22.6)   **48 (9.8)**                          21 (55.3)   101 (16.3)   \<2.2E-16
  Colistin          0 (0)                        0 (0)       0 (0)                                 0 (0)       0 (0)        \>0.05
  Sulfonamides      18 (51.4)                    20 (37.7)   **72 (14.6)**                         18 (47.4)   128 (20.7)   2.84*E*−11
  Trimethoprim      14 (40.0)                    19 (35.8)   **28 (5.7)**                          16 (42.1)   77 (12.5)    \<2.2E-16
  Nalidixic acid    14 (40.0)                    14 (26.4)   **29 (5.9)**                          12 (31.6)   69 (11.2)    6.22*E*−13
  Enrofloxacin      12 (34.3)                    10 (18.9)   **5 (1.0)**                           9 (23.7)    36 (5.8)     \<2.2E-16

AMC, amoxicillin + clavulanic acid.

1

Numbers indicate

p-

values (Fisher's exact test). Numbers in bold indicate statistically significant values. For each antibiotic, the Fisher's exact test was used to compare the proportions of resistant isolates among phylogroups. When the Fisher's exact test was significant, an analysis and graphic visualization of the proportions and their 95% confidence intervals (CI) were performed. A proportion was considered significant when its CI did not overlap at least one other CI.

###### 

Multidrug-resistance according to phylogroup.

  **Phylogroup**   **Total (*n*)**   **No. of isolates resistant to 0--7 antibiotic families^1^**   **No. of MDR**   **% of MDR**   ***p-*value (Fisher's exact test)**                                  
  ---------------- ----------------- -------------------------------------------------------------- ---------------- -------------- ------------------------------------- ---- ---- --- ---- ---- ------ ----------
  A                35                11                                                             1                7              1                                     4    1    3   7    16   45.7   
  B1               53                21                                                             6                6              7                                     9    4    0   0    20   37.7   
  B2               492               377                                                            44               27             23                                    14   7    0   0    44   8.9    
  D                38                11                                                             3                5              4                                     7    3    1   4    19   50.0   3.99E-17
  Total            618               420                                                            54               45             35                                    34   15   4   11   99   16.0   

1

Antibiotics considered for determination of multidrug-resistance: amoxicillin, ceftiofur, streptomycin, chloramphenicol, tetracyclines, sulfonamides-trimethoprim, and enrofloxacin. MDR, multidrug-resistance. Isolates considered as non-multidrug-resistant are those resistant to 0--2 antibiotic families, while isolates considered as multidrug-resistant are those resistant to 3--7 antibiotic families. The Fisher's exact test was used to compare the proportion of multidrug-resistant (MDR) isolates among phylogroups,

p-

value was calculated from the number of MDR isolates for each phylogroups.

###### 

Distribution of virulence-associated genes among the A, B1, B2, and D phylogroups (618 studied *Escherichia coli* isolates).

  **Virulence gene**   **Number (%) of isolates**   **Total**   ***p-*value^2^**                                 
  -------------------- ---------------------------- ----------- ------------------- --------------- ------------ -----------
  *papA*               13 (37.1)                    6 (11.3)    **306 (62.2)^1^**   4 (10.5)        329 (53.2)   \<2.2E-16
  *kpsMTII*            4 (11.4)                     2 (3.8)     307 (62.4)          **24 (63.2)**   337 (54.5)   1.31E-23
  *sfaS*               0 (0.0)                      0 (0.0)     **79 (16.1)**       0 (0.0)         79 (12.8)    1.19E-06
  *afaD*               0 (0.0)                      0 (0.0)     1 (0.2)             1 (2.6)         2 (0.3)      0.23
  *iutA*               19 (54.3)                    20 (37.7)   **48 (9.8)**        17 (44.7)       104 (16.8)   \<2.2E-16
  *fyuA*               16 (45.7)                    22 (41.5)   **402 (81.7)**      19 (50.0)       459 (74.3)   3.08E14
  *focG*               0 (0.0)                      2 (3.8)     **193 (39.2)**      1 (2.6)         196 (31.7)   \<2.2E-16
  *hlyD*               7 (20.0)                     3 (5.7)     **313 (63.6)**      3 (7.9)         326 (52.8)   \<2.2E-16
  *cnf1*               7 (20.0)                     2 (3.8)     **315 (64.0)**      2 (5.3)         326 (52.8)   \<2.2E-16
  *cdt3*               0 (0.0)                      1 (1.9)     0 (0.0)             0 (0.0)         1 (0.2)      1
  *fimH*               32 (91.4)                    47 (88.7)   422 (85.8)          32 (84.2)       533 (86.2)   0.78
  *iroN*               17 (48.6)                    22 (41.5)   294 (59.8)          21 (55.3)       354 (57.3)   0.051
  *ibeA*               6 (17.1)                     7 (13.2)    **162 (32.9)**      4 (10.5)        179 (29.0)   1.65E-4
  *iss*                9 (25.7)                     16 (30.2)   **59 (12.0)**       12 (31.6)       96 (15.5)    4.56E-05
  *eae*                2 (5.7)                      1 (1.9)     5 (1.0)             0 (0.0)         8 (1.3)      0.113
  Median VS^2^         3                            3           6                   4               6            --
  IQ min               1                            0           0                   0               0            --
  IQ max               9                            8           10                  8               10           --
  ExPEC                14 (40.0)                    7 (13.2)    **333 (67.7)**      15 (39.5)       369 (59.7)   2.54E-16
  UPEC                 7 (20.0)                     2 (3.8)     **263 (53.5)**      2 (5.3)         274 (44.3)   9.41E-22

1

Numbers indicate p-values (Fisher's exact test). Numbers in bold indicate statistically significant values.

2

p

-value (Fisher's exact test) calculated from the number of positive isolates for each virulence gene among phylogroups. When the Fisher's exact test was significant, an analysis and graphic visualization of the proportions and their 95% confidence intervals (CI) was performed. A proportion was considered significant when its CI did not overlap at least with one other CI.

2

VS is the Median virulence-associated gene Score calculated as the sum of virulence genes found positive using PCR. IQ: interquartile range of the virulence gene scores. ExPEC status was defined as the presence of ≥2 of the following genes:

papA, focG, kpsMTII

,

sfaS

,

afaD

, and

iutA.

UPEC status was defined as the presence of the

hlyD

and

cnf1

genes among ExPEC isolates. The virulence genes

cnf2

,

stx1

,

stx2

,

aggR

, and

cdt3

were absent from this population of isolates.

Univariate logistic regression model was implemented to assess the associations between ESBL or AmpC or pathology (here UTI) status and the presence of virulence genes: the ESBL (or AmpC or pathology) status was the dependent variable and each model included a bimodal explanatory variable related to the studied virulence gene regardless of the presence (or not) of other genes. The *p*-values, odds ratio (OR) and 95% confidence intervals were calculated by a logistic regression model univariate ([Table 4](#T4){ref-type="table"}). A multivariate model (taking into account the 12 virulence genes detected in this study as well as their interactions) could not be implemented since there were too many parameters to estimate in relation to the available data and the model would not converge. Associations were considered significant at *p* ≤ 0.05. R software version 3.6.0 (2019-04-26) was used for statistical analyses ([@B42]).

###### 

Association between ESBL, AmpC or UTI status, and virulence genes.

  **Status**   **Virulence gene**   ***p*-value**   **Odd Ratio**   **95% CI**
  ------------ -------------------- --------------- --------------- -----------------
  ESBL         *iutA*               4E-05           73.29           14.34--1,339.49
               *iroN*               0.03838         0.29            0.08--0.88
  AmpC         *kpsMII*             0.00156         0.09            0.01--0.33
  UTIs         *cnf1*               0.02353         1.47            1.05--2.05
               *focG*               0.0061          1.68            1.17--2.45
               *papA*               0.00104         1.75            1.25--2.45
               *sfaS*               0.03376         1.8             1.07--3.19
               *hlyD*               0.01498         1.51            1.08--2.11

The

p

-values, odds ratio and 95% confidence intervals (CI) were determined by univariate logistic regression.

Results {#S3}
=======

Distribution of Phylogroups and Lineages of Pathogenic *E. coli* From Dogs {#S3.SS1}
--------------------------------------------------------------------------

A total of 618 *E. coli* isolates were collected, of which 35 belonged to phylogroup A (5.7%), 53 to B1 (8.6%), 492 to B2 (79.6%) and 38 to phylogroup D (6.1%). Most isolates (65.2%) were associated with UTIs, but several other diseases were diagnosed ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}). In all diseases, B2 was by far the predominant phylogroup, ranging from 58.6% (*n* = 17, digestive tract infections) to 90% (*n* = 54, otitis) of the isolates ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}). According to this over-representation of the B2 phylogroup, complete MLST of a randomly chosen subset of 89 B2 *E. coli* revealed dominant STs, with ST372 (*n* = 16, 17.9%) and ST73 (*n* = 16, 17.9%) being the most frequent ([Figure 1](#F1){ref-type="fig"}). ST12 (*n* = 9), ST141 (*n* = 7), and ST961 (*n* = 5) were also repeatedly identified, and ST131 was detected in two animals. Sixteen STs were identified once, three twice and two STs were detected three times. Finally, six STs were not found in the Achtman database. To further decipher the major lineages composing the 492 B2 *E. coli* group, partial MLST was performed: the *fumC* allele was sequenced on all 403 remaining isolates, and the *purA* and *icd* alleles were subsequently sequenced on a subset of isolates to refine the analysis. Over the total number of B2 *E. coli*, 102 belonged to ST372 (102/492, 20.7%) and 99 to ST73 (20.1%), slightly modifying the previously estimated proportions of both STs (both initially estimated at 17.9%). The other STs were found in smaller numbers, with 37 isolates belonging to ST141 (7.5%), 13 to ST12 (2.6%), 12 to ST127 (2.4%), 9 to ST131 (1.8%), and 6 to ST961 (1.2%). Among the nine ST131, eight showed an unusual *fimH* variant, and the last one showed the *fimH*30 allelic variant.

![Phylogenetic proximity of 89 randomly chosen B2 isolates, as inferred using goeBURST (phyloviz). Each circle is a pie chart showing the pathologies from which the isolates were obtained. Digestive disease is colored in red, UTIs in dark blue, unknown pathology in light blue, skin infection in orange, otitis in light orange, reproduction disorder in green, respiratory disease in light green. The node size of the goeBURST is proportional to the number of isolates. Nodes are in log scale. Scaling factor = 2.](fmicb-11-00580-g001){#F1}

Resistance Profiles of Pathogenic *E. coli* From Dogs {#S3.SS2}
-----------------------------------------------------

Resistances to amoxicillin (27.5%), sulfonamides (20.7%), streptomycin (16.7%) and tetracyclines (16.3%) were most frequent ([Table 1](#T1){ref-type="table"}). Although phylogroups A, B1, and D include fewer isolates (*n* = 126) than phylogroup B2 (*n* = 492), isolates belonging to the former three phylogroups presented statistically much more resistances than isolates from phylogroup B2. For example, enrofloxacin resistance was observed in 1% of the B2 isolates (*n* = 5), but occurred in 24.6% of the non-B2 isolates (*n* = 31). This discrepancy was also clearly demonstrated by the occurrence of multidrug-resistance (resistance to ≥3 antibiotic families), which was detected in 8.9% of the B2 and 43.7% of the non-B2 isolates ([Table 2](#T2){ref-type="table"}).

ESC-resistance was identified in 33 isolates (5.3%), including 14 ESBL- and 19 AmpC-producing *E. coli*. All these latter isolates produced the CMY-2 enzyme and all ESBL-producing *E. coli* produced a CTX-M-type enzyme. CTX-M-15 was the most frequent (*n* = 10), followed by CTX-M-27 (*n* = 2), CTX-M-1 (*n* = 1) and CTX-M-3 (*n* = 1). The 19 CMY-2-producing *E. coli* presented very diverse genetic backgrounds, since 13 different STs were identified. Only *E. coli* ST12 and ST4608 were each detected in three different dogs. On the contrary, ST410 was identified in 7/14 of the ESBL-producing *E. coli*. Of note, one ST131 isolate producing CTX-M-27 belonged to the C1-M27 sub-clade. A single isolate was resistant to ertapenem (0.2%) and identified as an OXA-48 producer belonging to ST1485. All *bla*~CMY--2~ genes were carried by IncI1 plasmids. The *bla*~CTX--M--27~ and *bla*~CTX--M--1~ genes were located on IncF plasmids and the *bla*~OXA--48~ was carried by an IncL plasmid. In contrast, all *bla*~CTX--M--15~ genes were found on the bacterial chromosome.

Virulence Profiles of Pathogenic *E. coli* From Dogs {#S3.SS3}
----------------------------------------------------

Among the 618 isolates, 369 (59.7%) were classified as ExPEC (≥2 VFs among *papA*, *sfaS, focG*, *afaD*, *iutA*, *kpsMTII*). Most ExPEC isolates belonged to phylogroup B2 (*n* = 333/369, 90.2%). The proportion of ExPEC isolates from phylogroup B2 was 67.7% (*n* = 333/492) and significantly lower in phylogroup B1 (*n* = 7/53, *p* = 2.54E-16) ([Table 3](#T3){ref-type="table"}). A total of 274 ExPEC were sub-pathotyped as UPEC (ExPEC + *hlyD* and *cnf1*). Among the 274 UPEC, 196 (71.5%) isolates were associated with UTIs, 24 (8.8%) with otitis, 13 (4.7%) with reproduction disorder, 8 (2.9%) with skin infection, 8 (2.9%) with digestive disease, 7 (2.5%) with respiratory diseases and 18 (6.6%) were from unknown pathology. The significance of UPEC isolates among digestive tract infections can be questioned. Given the low number of isolates (*n* = 8), this may be due to the transitory presence of a B2 isolate in the gastrointestinal tract. UPEC isolates belonged to B2 for the most part (*n* = 263/274, 96.0%, *p* = 1.53E-23). The proportion of UPEC among B2 isolates reached 53.5% (*n* = 263/492) ([Table 3](#T3){ref-type="table"}) and 43% of UPEC belonged to ST372 (*n* = 59/105) or ST73 (*n* = 56/99).

Virulence gene scores varied from 0 to 10 among phylogroups. The median virulence gene score was higher in phylogroup B2 than in the A, B1, and D phylogroups ([Table 3](#T3){ref-type="table"}). However, the distribution of virulence-associated genes varied among phylogroups ([Supplementary Figure S1](#FS1){ref-type="supplementary-material"} and [Table 3](#T3){ref-type="table"}). The siderophore-encoding *fyuA* gene was the most frequently identified virulence factor (81.7%) in the B2 group. This *fyuA* gene, along with *papA* (adhesin, 62.2%), *kpsMTII* (protectin, 62.4%), *sfaS* (adhesin, 16.1%), *focG* (adhesin, 39.2%), *hlyD* (toxin, 63.6%), *cnf1* (toxin, 64%) and *ibeA* (invasin, 32.9%), was highly associated with phylogroup B2 ([Table 3](#T3){ref-type="table"}). On the contrary, the proportions of the *iutA* (siderophore, 9.8%) and *iss* (protectin, 12.0%) genes were significantly lower in B2 isolates ([Table 3](#T3){ref-type="table"}). The *papA* (*p* = 0.053), *fyuA* (*p* = 4.3E-5), *focG* (6.44E-11), *hlyD* (*p* = 0.007) and *cnf1* (0.013) VFs were related to ST372 compared to the other isolates using the Fisher's exact test. *focG* (*p* = 3.21E-4), *hlyD* (*p* = 0.011) and *cnf1* (*p* = 0.006) were also linked to ST73. The *iutA* (*p* = 0.021), *kpsMTII* (*p* = 0.031) and *iss* (*p* = 1.4E-4) genes were rarely found in ST372. The virulence profiles among UTI-associated ESBLs and AmpC were described in [Table 5](#T5){ref-type="table"} and [Supplementary Table S3](#TS3){ref-type="supplementary-material"}.

###### 

Molecular characteristics of the 34 extended-spectrum cephalosporin- and carbapenem-resistant isolates.

  **Strain**   **Pathology**        **Sequence type**   **Phylogroup**   **Phenotype**   **Beta-lactamase enzyme**   **Associated resistances**                    **Virulence profiles**
  ------------ -------------------- ------------------- ---------------- --------------- --------------------------- --------------------------------------------- ----------------------------------------------------------
  A14          UTI                  191                 A                AmpC            CMY-2                       None                                          *fimH*
  A08          UTI                  NT                  B2               AmpC            CMY-2                       CHL, TET, SUL, TMP, NAL                       *fimH, iutA, iroN*
  B03          UTI                  4,608               D                AmpC            CMY-2                       STR, KAN, GEN, CHL, TET, SUL, TMP, NAL, ENR   *fimH, cnf1, papA, hlyD, iutA, iroN, iss, fuyA*
  C05          Unknown              12                  B2               AmpC            CMY-2                       None                                          *fimH, cnf1, focG, papA, hlyD, iroN, ibeA, fuyA*
  D08          UTI                  372                 B2               AmpC            CMY-2                       None                                          *fimH, focG, ibeA, fuyA*
  D09          Reproductive tract   1,706               B1               AmpC            CMY-2                       None                                          *fimH*
  E03          UTI                  297                 B1               AmpC            CMY-2                       STR, SUL, TMP                                 *fimH*
  F06          UTI                  4,608               D                AmpC            CMY-2                       STR, KAN, GEN, CHL, TET, SUL, TMP, NAL, ENR   *papA, iutA, iss*
  F10          UTI                  12                  B2               AmpC            CMY-2                       STR, KAN, CHL, SUL, NAL                       *fimH, cnf1, papA, hlyD, iroN, fuyA*
  I54          Unknown              141                 B2               AmpC            CMY-2                       STR, CHL, TET, SUL                            *fimH, cnf1, papA, hlyD, iroN, fuyA*
  I58          Otitis               162                 B1               AmpC            CMY-2                       STR, TET, SUL, NAL, ENR                       *fim, fuyA*
  K26          UTI                  212                 B1               AmpC            CMY-2                       None                                          *fimH*
  N19          Digestive            NT                  B2               AmpC            CMY-2                       None                                          *focG, fimH, fuyA*
  Q05          UTI                  4,608               D                AmpC            CMY-2                       STR, KAN, GEN, CHL, TET, SUL, TMP, NAL, ENR   *fimH, cnf1, papA, hlyD, iutA, iroN, fuyA*
  Q29          Digestive            1,011               D                AmpC            CMY-2                       STR, TET, SUL, TMP, NAL, ENR                  *fimH, iroN, ibeA*
  R07          UTI                  2,015               B2               AmpC            CMY-2                       None                                          *fimH, cnf1, kpsMII, papA, iroN, ibeA, fuyA*
  T11          UTI                  68                  D                AmpC            CMY-2                       NAL                                           *kpsMII, fimH, fuyA*
  X25          UTI                  372                 B2               AmpC            CMY-2                       None                                          *fimH, cnf1, focG, papA, sfaS, hlyD, fuyA*
  Z01          Respiratory          12                  B2               AmpC            CMY-2                       None                                          *fimH, cnf1, focG, papA, hlyD, iroN, fuyA*
  T12          Respiratory          1,485               D                Carbapenemase   OXA-48                      STR, TET, SUL, TMP                            *kpsMII, fimH*
  B04          UTI                  410                 A                ESBL            **CTX-M-15^3^**             STR, KAN, GEN, CHL, TET, SUL, TMP, NAL, ENR   *fimH, cnf1, papA, hlyD, iutA, fuyA*
  B11          UTI                  648                 D                ESBL            CTX-M-3                     STR, KAN, GEN, CHL, TET, SUL, TMP, NAL, ENR   *fimH, kpsMII, iutA*
  C17          UTI                  131                 B2               ESBL            CTX-M-27                    NAL, ENR                                      *fimH, kpsMII, iutA*
  E08          UTI                  410                 A                ESBL            **CTX-M-15**                STR, KAN, GEN, CHL, TET, SUL, TMP, NAL, ENR   *papA, iutA*
  H20          UTI                  90                  A                ESBL            CTX-M-27                    STR, TET, SUL, TMP, NAL, ENR                  *fimH*
  I47          UTI                  372                 B2               ESBL            **CTX-M-15**                CHL                                           *kpsMII, iutA, ibeA, fuyA*
  N01          UTI                  410                 A                ESBL            **CTX-M-15**                STR, KAN, GEN, CHL, TET, SUL, TMP, NAL, ENR   *fimH, cnf1, papA, hlyD, iutA, ibeA, fuyA*
  N11          UTI                  410                 A                ESBL            **CTX-M-15**                STR, KAN, GEN, CHL, TET, SUL, TMP, NAL, ENR   *fimH, cnf1, papA, hlyD, iutA, fuyA*
  N20          UTI                  410                 A                ESBL            **CTX-M-15**                STR, KAN, GEN, CHL, TET, SUL, NAL, ENR        *cnf1, papA, hlyD, iutA, fuyA*
  P24          UTI                  23                  A                ESBL            CTX-M-1                     TET, SUL, TMP                                 *fimH, iutA, iroN, ibeA*
  T01          UTI                  410                 A                ESBL            **CTX-M-15**                STR, KAN, GEN, CHL, TET, SUL, TMP, NAL, ENR   *fimH, cnf1, papA, hlyD, iutA, iroN, fuyA*
  T03          Reproductive tract   NT                  A                ESBL            **CTX-M-15**                STR, KAN, GEN, CHL, TET, SUL, TMP, NAL, ENR   *fimH, cnf1, kpsMII, papA, hlyD, iutA, iroN, ibeA, fuyA*
  T13          UTI                  648                 D                ESBL            **CTX-M-15**                KAN, TET, NAL, ENR                            *kpsMII, papA, afa, hlyD, iutA, iroN, ibeA, fuyA*
  Z09          UTI                  410                 A                ESBL            **CTX-M-15**                STR, KAN, GEN, CHL, TET, SUL, TMP, NAL, ENR   *fimH, cnf1, papA, hlyD, iutA, fuyA*

UTI: urinary tract infection.

1

Antibiotics: STR, streptomycin; KAN, kanamycin; GEN, gentamicin; CHL, chloramphenicol; TET, tetracycline; SUL, sulfonamides; TMP, trimethoprim; NAL, nalidixic acid, ENR, enrofloxacin.

2

The A08 isolate is a

fumC

variant of ST58; N19 is a

gyrB

variant of ST372; T03 is a

purA

variant of ST410.

3

In bold are all isolates that are chromosomally encoded as shown by Southern blots on I-

Ceu

I PFGE.

The univariate logistic regression model showed that *iutA* was most frequently present in ESBL-producing isolates, but the *iroN* and *kpsMTII* genes were less frequently present in ESBL- or AmpC-positive isolates. The *cnf1*, *focG*, *papA*, *sfaS*, and *hlyD* genes mostly found in B2 were also associated with UTIs ([Table 4](#T4){ref-type="table"}).

Whole Genome Sequencing of Pathogenic *E. coli* From Dogs {#S3.SS4}
---------------------------------------------------------

WGS was further performed on a subset of 14 UPEC isolates representative of the main STs found in dogs. Additional VFs such as *gad* (glutamate decarboxylase), *mcmA* (methylmalonyl-CoA mutase), *mch* operon involved in biosynthesis, *pic* (serine protease autotransporter), *vat* (vacuolating autotransporter toxin), *ireA* (iron-regulated outer membrane) and *ihA* (iron-regulated gene homologue adhesion) were detected in all UPEC ([Supplementary Table S2](#TS2){ref-type="supplementary-material"}). The serotypes of these UPEC were respectively O15:H31 (*n* = 1), O2:H1 (*n* = 1), O2:H14 (*n* = 1), O2:H6 (*n* = 1), O25:H1, O25:H4, O4:H31 (*n* = 1), O4:H5 (*n* = 1), O6/O4:H1/H5 (*n* = 1), O6:H1 (*n* = 2) ([Supplementary Table S2](#TS2){ref-type="supplementary-material"}). Apart from the *mdf*(A) gene which was present in all isolates, only four isolates presented additional resistance genes ([Supplementary Table S2](#TS2){ref-type="supplementary-material"}). The phenotypes observed by disc diffusion for these four isolates totally matched with the detected genes.

Discussion {#S4}
==========

In this study, we showed that the population structure of *E. coli* isolated from diseased dogs was clearly dominated by the B2 phylogroup, which accounted for 79.6% of all *E. coli* isolates. The predominance of the B2 phylogroup was most likely associated with the study design. Other studies on diseased animals with no AMR criteria have also reported high proportions of the B2 phylogroup ([@B32]; [@B30]), and studies from healthy animals and/or focusing on ESC-resistant *E. coli* tended to report non-B2 phylogroups ([@B52]). A recent exception to this pattern is a study on clinical ESC-R *E. coli* in dogs in France, which reported a high prevalence of multidrug-resistant B2 *E. coli*, but mainly linked to a high prevalence of ST131/H30 isolates ([@B38]). The low prevalence of ST131/H30 in our study confirms this clone as a human-associated pathogenic *E. coli* lineage, which occasionally transfers to companion animals.

In the present study, ST372 and ST73 were by far the dominant STs representing 20.7 and 20.1% of the B2 isolates, respectively. The seven ST372, ST73, ST141, ST12, ST127, ST131, and ST961 comprised 56.3% of all B2 isolates, which is very similar to what has been described in the United States in a study with comparable settings ([@B30]). Similar findings in these two geographic areas strongly suggest a dog-specific distribution of pathogenic *E. coli* clones rather than the effect of regional factors. Of note, among the nine ST131 identified in this study, eight did not belong to the human-associated ST131 sublineages and carried unknown *fimH* variants. The last isolate produced a CTX-M-27 enzyme and belonged to the newly described C1-M27 clade. This clade first emerged in Japan before being identified in humans in other countries and continents. It has only recently been described in dogs -- concomitantly in France and the United Kingdom -- and this new occurrence of a C1-M27/ST131 isolate in a dog proves that this clade is not restricted to humans ([@B4]; [@B38]).

ST372, which has already been reported in dogs and much more sporadically in humans ([@B1]; [@B52]), is thus emerging as a major dog-associated ST that occasionally carries resistance genes, as described here for ESBLs. Of note, ST372 was also recently reported as an OXA-48 producer ([@B37]). Its frequency in dogs most likely relies upon specific host adaptation abilities, allowing its spread in France and the United States despite the fact that the two countries differ in terms of antibiotic treatments, especially since France has set up a National Action Plan in 2012 to reduce antibiotic use ([@B2]). Nonetheless, an Australian study on dogs reported the absence of ST372, which may be due to the strong border policies to avoid importation of foreign animals, but also most likely to the fact that only healthy and not clinical animals were sampled ([@B5]). Apart from ST372, other frequent clones were human-associated STs, such as ST73, ST12, or ST127. Though usually considered a human-specific lineage, ST73 is most probably an ubiquitous urinary pathogen, because it has recurrently been described in animals, both in diseased and healthy contexts ([@B52]; [@B31]; [@B5]). Also, ST73 may well be under-reported in the literature because most papers have focused on ESC-R genes, which are less frequently found in this ST than in other ones such as ST131 or ST38 ([@B24]; [@B34]; [@B51]).

The prevalence of ESC-R *E. coli* in this study was 5.3% (33/618), which is fairly low compared with what has recently been described in the United Kingdom (18.4%), Switzerland (32.1%) or even in France in 2011 (18.5%) ([@B55]; [@B4]). This low prevalence may result from the strong policy measures on AMR in the vet sector since 2012 through the National Action Plan Ecoantibio, which resulted in a 65.5% decrease in the use of last-generation cephalosporins in cats and dogs between 2013 and 2017 ([@B2]). Yet, despite these efforts, carbapenem-resistant *E. coli* isolates are emerging in dogs with no apparent risk factors. ST1485 OXA-48 *E. coli* found here is the second report of an OXA-48-producing *E. coli* after the occurrence of an OXA-48 ST372 *E. coli* in a healthy dog in 2015 ([@B37]). It questions the origin of these isolates since, unlike in other countries, the use of carbapenems is totally forbidden in France, even in emergency veterinary medicine. The emergence of OXA-48 in dogs has also been demonstrated in neighboring countries such as Germany ([@B41]), so that monitoring of carbapenem-resistance in companion animals is now strongly recommended.

Among ESC-R isolates, the fluoroquinolone-resistant ST410 clone was found in 7/14 of the ESBL-producing *E. coli*. ST410 has recently been claimed to be an international high-risk clone, similar to ST131 in humans, for its capacity to combine resistance and virulence determinants as well as to cause hospital outbreaks ([@B44]). ST410 has been reported in dogs mostly in Europe (Germany, Switzerland, United Kingdom), but also in the United States; therefore, its emergence as a major ESBL-producing pathogen in dogs should be monitored ([@B17]; [@B48]; [@B30]; [@B56]; [@B4]). In this study, our samples originated from dogs that had no epidemiological link among each other. However, all animals visited veterinary hospitals working closely with the veterinary laboratories involved, so that it may be hypothesized that this clone is circulating in veterinary hospitals. However, this remains to be proven since other sources (such as a high prevalence in the community) cannot be excluded. The *bla*~CTX--M--15~ gene associated with ST410 was systematically carried on the bacterial chromosome, as already reported in Germany ([@B17]). Interestingly, the three remaining *bla*~CTX--M--15~ genes found on a single-locus variant of ST410, ST372, and ST648, respectively, were also found on the chromosome. Chromosomal insertion of *bla*~CTX--M~ genes has long been considered as less frequent than their location on plasmids, but recent convergent studies suggest that it would probably be worth reconsidering this point. The factors driving chromosomal insertions are unclear. They may potentially involve bacterial fitness and certainly deserve further investigation. ST648 has also been described as a pandemic clone in animals, and has been recurrently associated either with ESBL or pAmpC enzymes ([@B16]; [@B36]). In this study, it was identified twice as an ESBL carrier.

In agreement with previous studies, most VFs related to UPEC (*cnf1*, *focG*, *papA*, *sfaS*, and *hlyD*) were found in isolates from the B2 phylogroup. Our data confirm the low prevalence of the UPEC-associated VFs among resistant isolates, and especially in ESC-R isolates ([@B22]; [@B23]). *iutA* was the only exception, because this virulence gene was most frequently present in ESBL-producing *E. coli*, as previously suggested ([@B30]). A strong correlation between the UPEC-associated VFs and the primarily dog-associated ST372 was demonstrated here. Among the VFs, *cnf1*, and *hlyD* were associated with both ST372 and ST73. Most VFs and serotypes identified in this study using the WGS analysis have been previously characterized in UPEC strains related to UTIs ([@B27]; [@B54]; [@B47]). All these results suggest a link between UPEC-associated VFs, B2 phylogroup, ST372/ST73 and UTIs in dogs.

In conclusion, to our best knowledge based on the largest pathogenic *E. coli* collection in dogs, our study showed that the population of *E. coli* in this animal species was dominated by ExPEC lineages. Although ST372 is most probably largely adapted to dogs, the human-associated ST73 appears more ubiquitous than previously thought. We also showed a clear discrepancy between resistance phenotypes and virulence-associated genes, which clustered in the non-B2 and B2 isolates, respectively. Considering that ESC-R *E. coli* only account for 5.3% of the population, but B2 isolates represent 79.6% of this same population, transmission of virulent ExPEC/UPEC lineages may well be the issue, rather than the transmission of ESC-R isolates. The risk for humans of being infected or colonized by such isolates remains to be determined. Further studies on *E. coli* populations from various hosts, irrespective of their AMR status, are surely needed to refine the scientific opinions on risks associated with inter-sectorial transfers of pathogenic *E. coli* in a "One Health" approach.
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